RedHill Biopharma (RDHL) Tuesday announced that it has launched a Phase 2 trial to assess opaganib's ability to enhance darolutamide in treating metastatic castrate-resistant prostate cancer or mCRPC.
Supported by Bayer and the Ramsay Hospital Research Foundation, the 80-patient study, led by Professor Lisa Horvath, aims to improve 12-month radiographic progression-free survival. Using the PCPro biomarker, it targets patients resistant to standard treatment.
Opaganib, a sphingosine kinase-2 (SPHK2) inhibitor, may help overcome drug resistance. With prostate cancer affecting 1.5 million people annually, this research could lead to a breakthrough in managing treatment-resistant mCRPC and improving patient outcomes.
RDHL closed Tuesday's trading at $5.82 up 1.22 percent or $0.07 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.